Mast Therapeutics Reports Update on Epic Study Enrollment, Offers '15 Milestones

By: via Benzinga
Mast Therapeutics, Inc. (NYSE: MSTX), a clinical-stage biopharmaceutical company, today reported that enrollment in its pivotal EPIC ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.